Tonix Pharmaceuticals Holding (TNXP) Enterprise Value (2014 - 2026)

Tonix Pharmaceuticals Holding has reported Enterprise Value for 13 years, with the latest figure at $38.0 million in Q2 2026.

• On a quarterly basis, Enterprise Value fell 73.82% year-over-year to $38.0 million in Q2 2026; TTM through Jun 2026 was $38.0 million, a 73.82% decrease from a year earlier, with the FY2025 full-year figure at -$74.7 million, up 0.92% from the prior year.
• Enterprise Value was $38.0 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $9.9 million in the prior quarter.
• The five-year high for Enterprise Value was $145.3 million in Q2 2025, with the low at -$117.7 million in Q3 2022.
• Average Enterprise Value over 5 years is -$18.3 million, with a median of -$10.6 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value plunged 762.33% in 2024, then jumped 11306.08% in 2025.
• Over 5 years, Enterprise Value stood at -$106.5 million in 2022, then jumped by 82.13% to -$19.0 million in 2023, then slumped by 296.05% to -$75.4 million in 2024, then climbed by 0.92% to -$74.7 million in 2025, then surged by 150.93% to $38.0 million in 2026.
• The last three Enterprise Value figures came in at $38.0 million (Q2 2026), $9.9 million (Q1 2026), and -$74.7 million (Q4 2025), per Business Quant data.